The emergence of acquired resistance represents a fundamental challenge in the management of EGFR-mutant non-small cell lung cancer (NSCLC) treated with tyrosine kinase inhibitors (TKIs). This evidence concerns the gene EGFR and non-small cell lung carcinoma.